Epigenomics AG

Company Profile

Epigenomics AG had its IPO on under the ticker symbol EPGNY.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Epigenomics AG has a staff strength of 36 employees.

Stock update

Shares of Epigenomics AG opened at $9.52 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.52 - $9.56, and closed at $9.56.

This is a +4.37% increase from the previous day's closing price.

A total volume of 212 shares were traded at the close of the day’s session.

In the last one week, shares of Epigenomics AG have slipped by -22.02%.

Epigenomics AG's Key Ratios

Epigenomics AG has a market cap of $6.44 million, indicating a price to book ratio of 0.5316 and a price to sales ratio of 13.7898.

In the last 12-months Epigenomics AG’s revenue was $567000 with a gross profit of $6.07 million and an EBITDA of $-8677000. The EBITDA ratio measures Epigenomics AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Epigenomics AG’s operating margin was -1589.59% while its return on assets stood at -24.5% with a return of equity of -38.02%.

In Q3, Epigenomics AG’s quarterly earnings growth was a positive 0% while revenue growth was a negative 97.5%.

Epigenomics AG’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Epigenomics AG’s profitability.

Epigenomics AG stock is trading at a EV to sales ratio of 0.4487 and a EV to EBITDA ratio of 1.4907. Its price to sales ratio in the trailing 12-months stood at 13.7898.

Epigenomics AG stock pays annual dividends of $0 per share, indicating a yield of 2.9% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$18.97 million

Total Liabilities

$4.36 million

Operating Cash Flow

$-152000.00

Capital Expenditure

$162000

Dividend Payout Ratio

0%

Epigenomics AG ended 2024 with $18.97 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.97 million while shareholder equity stood at $13.93 million.

Epigenomics AG ended 2024 with $0 in deferred long-term liabilities, $4.36 million in other current liabilities, 16357000.00 in common stock, $-98678000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.77 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Epigenomics AG’s total current assets stands at $16.89 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $128000.00 compared to accounts payable of $1.12 million and inventory worth $217000.00.

In 2024, Epigenomics AG's operating cash flow was $-152000.00 while its capital expenditure stood at $162000.

Comparatively, Epigenomics AG paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.56

52-Week High

$9.56

52-Week Low

$8.02

Analyst Target Price

$

Epigenomics AG stock is currently trading at $9.56 per share. It touched a 52-week high of $9.56 and a 52-week low of $9.56. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $149.48 and 200-day moving average was $525.97 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.